{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:55:40Z","timestamp":1785700540369,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.trim.2026.102415","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:25:18Z","timestamp":1782170718000},"page":"102415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"97","author":[{"given":"Eshak I.","family":"Bahbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Elshabasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.trim.2026.102415_bb0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"26","key":"10.1016\/j.trim.2026.102415_bb0010","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"July","key":"10.1016\/j.trim.2026.102415_bb0015","article-title":"Efficacy and safety of axatilimab in chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"215","author":"Bahbah","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.trim.2026.102415_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.trim.2026.102415_bb0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease","volume":"21","author":"Baird","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.trim.2026.102415_bb0035","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bbmt.2020.01.014","article-title":"Nilotinib treatment of patients affected by chronic graft-versus-host disease reduces collagen production and skin fibrosis by downmodulating the TGF-\u03b2 and p-SMAD pathway","volume":"26","author":"Marinelli Busilacchi","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.trim.2026.102415_bb0040","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ajpath.2012.07.017","article-title":"Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease","volume":"181","author":"Zerr","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.trim.2026.102415_bb0045","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41409-018-0158-9","article-title":"Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib","volume":"53","author":"van der Wagen","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.trim.2026.102415_bb0050","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41409-020-0902-9","article-title":"Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)","volume":"55","author":"Olivieri","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.trim.2026.102415_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41409-022-01898-x","volume":"58","author":"Srour","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.trim.2026.102415_bb0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbmt.2017.10.021","article-title":"Anti-PDGFRA antibodies predict for response to nilotinib in steroid refractory \/ dependent cGvHD","volume":"24","author":"Chen","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.trim.2026.102415_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.trim.2026.102415_bb0070","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.trim.2026.102415_bb0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41409-018-0429-5","article-title":"Tyrosine kinase inhibitor levels matter in treating chronic GVHD","volume":"54","author":"van der Wagen","year":"2019","journal-title":"Bone Marrow Transplant. England"},{"issue":"21","key":"10.1016\/j.trim.2026.102415_bb0080","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V116.21.2329.2329","article-title":"Nilotinib as salvage therapy in patients with chronic graft versus host disease","volume":"116","author":"Terriou","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.trim.2026.102415_bb0085","article-title":"A phase 1 open label, dose escalation study of nilotinib in steroid dependent\/refractory chronic graft-versus-host disease","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.trim.2026.102415_bb0090","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium","volume":"5","author":"De Filipp","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.trim.2026.102415_bb0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.trim.2026.102415_bb0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","article-title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","volume":"43","author":"Mayr","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:39:04Z","timestamp":1785699544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S0966327426000730"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102415","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102415"}}